This company has been marked as potentially delisted and may not be actively trading. Nightstar Therapeutics (NITE) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock NITE vs. PRME, PLX, IKT, CVM, ZIVO, IZTC, CRTX, JATT, ALVR, and FNCHShould you be buying Nightstar Therapeutics stock or one of its competitors? The main competitors of Nightstar Therapeutics include Prime Medicine (PRME), Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), CEL-SCI (CVM), ZIVO Bioscience (ZIVO), Invizyne Technologies (IZTC), Cortexyme (CRTX), JATT Acquisition (JATT), AlloVir (ALVR), and Finch Therapeutics Group (FNCH). These companies are all part of the "medical" sector. Nightstar Therapeutics vs. Its Competitors Prime Medicine Protalix BioTherapeutics Inhibikase Therapeutics CEL-SCI ZIVO Bioscience Invizyne Technologies Cortexyme JATT Acquisition AlloVir Finch Therapeutics Group Prime Medicine (NYSE:PRME) and Nightstar Therapeutics (NASDAQ:NITE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings. Do analysts rate PRME or NITE? Prime Medicine currently has a consensus target price of $8.92, indicating a potential upside of 119.08%. Given Prime Medicine's stronger consensus rating and higher probable upside, research analysts clearly believe Prime Medicine is more favorable than Nightstar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75Nightstar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of PRME or NITE? 70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 32.8% of Nightstar Therapeutics shares are owned by institutional investors. 22.7% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, PRME or NITE? Prime Medicine has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500. Comparatively, Nightstar Therapeutics has a beta of 2.84, suggesting that its share price is 184% more volatile than the S&P 500. Does the media refer more to PRME or NITE? In the previous week, Prime Medicine had 3 more articles in the media than Nightstar Therapeutics. MarketBeat recorded 3 mentions for Prime Medicine and 0 mentions for Nightstar Therapeutics. Prime Medicine's average media sentiment score of 0.26 beat Nightstar Therapeutics' score of 0.00 indicating that Prime Medicine is being referred to more favorably in the media. Company Overall Sentiment Prime Medicine Neutral Nightstar Therapeutics Neutral Is PRME or NITE more profitable? Nightstar Therapeutics' return on equity of -30.89% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Prime MedicineN/A -107.87% -74.97% Nightstar Therapeutics N/A -30.89%-27.65% Which has stronger valuation & earnings, PRME or NITE? Nightstar Therapeutics has lower revenue, but higher earnings than Prime Medicine. Nightstar Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrime Medicine$4.96M110.40-$198.13M-$1.56-2.61Nightstar TherapeuticsN/AN/A-$36.86M-$1.26-27.22 SummaryPrime Medicine beats Nightstar Therapeutics on 10 of the 15 factors compared between the two stocks. Get Nightstar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NITE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NITE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NITE vs. The Competition Export to ExcelMetricNightstar TherapeuticsBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.15B$287.07M$5.79B$10.15BDividend YieldN/AN/A5.69%4.60%P/E Ratio-27.22N/A74.5925.92Price / SalesN/A420.31453.5485.33Price / CashN/A22.4437.0859.91Price / Book5.8210.9112.156.29Net Income-$36.86M-$111.61M$3.28B$270.77M Nightstar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NITENightstar TherapeuticsN/A$34.30+1.8%N/A+40.0%$1.15BN/A-27.2247PRMEPrime Medicine3.2887 of 5 stars$3.27+4.6%$8.92+173.1%-0.2%$439.38M$4.96M-1.59234PLXProtalix BioTherapeutics2.5296 of 5 stars$1.64-0.3%$15.00+817.4%+67.3%$130.36M$61.95M-12.58200Positive NewsIKTInhibikase Therapeutics1.4724 of 5 stars$1.74-1.1%$6.50+273.6%+27.3%$129.66MN/A-0.656CVMCEL-SCI1.5982 of 5 stars$11.72-3.7%N/A-72.2%$80.62MN/A-24.4143Positive NewsShort Interest ↓ZIVOZIVO Bioscience0.3554 of 5 stars$17.00-2.9%N/A-3.7%$64.89M$15.85K-3.4810News CoverageGap DownIZTCInvizyne TechnologiesN/A$9.70flatN/AN/A$60.64MN/A0.0029News CoverageGap DownCRTXCortexymeN/A$1.60flatN/A+119.0%$48.24MN/A-0.5455JATTJATT AcquisitionN/A$2.02-1.0%N/A-41.1%$34.85MN/A0.003High Trading VolumeALVRAlloVirN/A$4.00-2.0%N/A-73.8%$20.17MN/A-0.20110High Trading VolumeFNCHFinch Therapeutics Group1.407 of 5 stars$12.03-7.5%N/A+7.8%$19.32MN/A-1.36190Positive NewsShort Interest ↓Gap Down Related Companies and Tools Related Companies PRME Alternatives PLX Alternatives IKT Alternatives CVM Alternatives ZIVO Alternatives IZTC Alternatives CRTX Alternatives JATT Alternatives ALVR Alternatives FNCH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NITE) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored6-Figure Target for BTC by 2025Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nightstar Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Nightstar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NITE Stock Alerts